Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
Keine aktuellen Veranstaltungen.
Vergangene Veranstaltungen (max. 10)
-
WiSe 2023
-
SoSe 2021
- Klinische Nuklearmedizin: Grundlagen und Indikationen
- Anleitung zu selbständigen wissenschaftlichen Arbeiten in der Nuklearmedizin
- begl. Vorlesung: Bildgebende Verfahren, Strahlenbehandlung, Strahlenschutz - Teil 2
- Der nuklearmedizinische Fall der Woche: Bildbeispiele, Indikationen und Grundlagen
- Kurs: Bildgebende Verfahren, Strahlenbehandlung, Strahlenschutz - Teil 3
- Kurs: Bildgebende Verfahren, Strahlenbehandlung, Strahlenschutz - Teil 1
- PJ - Seminar
- Kurs: Bildgebende Verfahren, Strahlenbehandlung, Strahlenschutz - Teil 2
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
90Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous TumorsIn: Journal of Nuclear Medicine (JNM), Jg. 66, 2025, Nr. 9, S. 1378 – 1384
-
Corrigendum to “Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management : Results from a Prospective Multicenter Randomized Phase 3 TrialIn: European Urology, Jg. 87, 2025, Nr. 1, S. 97 – 99
-
Evaluation of Surgical Margins with Intraoperative PSMA PET/CT and their Prognostic Value in Radical ProstatectomyIn: Journal of Nuclear Medicine (JNM), Jg. 66, 2025, Nr. 3, S. 352 – 358
-
Fibroblast-directed PET imaging reveals a case of retroperitoneal fibrosis after immunotherapy for metastatic urothelial cancer of the upper tractIn: Urology Case Reports, Jg. 61, 2025, 103105DOI (Open Access)
-
Fully Automated Image-Based Multiplexing of Serial PET/CT Imaging for Facilitating Comprehensive Disease PhenotypingIn: Journal of Nuclear Medicine (JNM), Jg. 66, 2025, Nr. 11, S. 1818 – 1826
-
Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [¹⁸F]FDG in gynaecological malignancies : systematic literature review and meta-analysisIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 52, 2025, Nr. 11, S. 3975 – 3989DOI (Open Access)
-
Head-to-head comparison of ⁶⁸ Ga-FAPI-46 PET/CT, ¹⁸F-FDG PET/CT, and contrast-enhanced CT for the detection of various tumorsIn: Annals of Nuclear Medicine, Jg. 39, 2025, Nr. 3, S. 255 – 265
-
High incidence and poor prognosis of bone metastases in functioning small intestinal neuroendocrine tumorsIn: Frontiers in Endocrinology, Jg. 16, 2025, 1680209DOI (Open Access)
-
Hormonsyndrome bei neuroendokrinen Tumoren : Richtig diagnostizieren und behandelnIn: Die Gastroenterologie, 2025, in press
-
Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving peptide receptor radionuclide therapyIn: Frontiers in Endocrinology, Jg. 16, 2025, 1526470DOI, Online Volltext (Open Access)
-
Incidence and Survival of Patients With Prostate Cancer in North-Rhine Westphalia, GermanyIn: Clinical Genitourinary Cancer, Jg. 23, 2025, Nr. 1, 102289DOI (Open Access)
-
Lenvatinib as salvage therapy in advanced and progressive GI-NETIn: Endocrine-Related Cancer, Jg. 32, 2025, Nr. 8, e250165
-
Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer : Retrospective Study from CHAARTED to PSMA PET ; An International MulticenterIn: Journal of Nuclear Medicine (JNM), Jg. 66, 2025, Nr. 1, S. 54 – 60
-
Multitracer comparison of gold standard PSMA-PET/CT with 68Ga-FAPI and 18F-FDG in high-risk prostate cancer : a proof-of-concept studyIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 52, 2025, Nr. 13, S. 4860 – 4869
-
Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary CancersIn: European Urology, Jg. 87, 2025, Nr. 2, S. 125 – 139
-
PET imaging utilization and trends in Germany : a comprehensive surveyIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 52, 2025, Nr. 12, S. 4390 – 4398DOI (Open Access)
-
PSMA-Radioligandentherapie : State of the ArtIn: Die Urologie, Jg. 64, 2025, Nr. 10, S. 1093 – 1104
-
Pathologic Complete Response Predicts Long-Term Survival Following Neoadjuvant Induction Chemotherapy and Chemo-Radiotherapy in Stage-III Non-Small Cell Lung CancerIn: Thoracic Cancer, Jg. 16, 2025, Nr. 22, e70183DOI (Open Access)
-
Potential value of [⁶⁸Ga]Ga-FAPI-46 PET in patients with metastatic urothelial carcinoma : A bi-centric analysisIn: European Journal of Nuclear Medicine and Molecular Imaging, 2025, in pressDOI (Open Access)
-
Prognostic value of PSMA PET/CT-Based local staging in predicting biochemical recurrence after radical prostatectomyIn: European Journal of Nuclear Medicine and Molecular Imaging, 2025, in pressDOI (Open Access)
-
Prognostic value of [¹⁸F]FDG- and PSMA-PET in patients evaluated for [¹⁷⁷Lu]Lu-PSMA therapy of mCRPCIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 52, 2025, Nr. 9, S. 3199 – 3210DOI (Open Access)
-
Prostate-specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy : Modeling long-term survivalIn: Cancer, Jg. 131, 2025, Nr. 21, e70131
-
Prostate-specific membrane antigen positron-emission tomography for novel risk-stratification of biochemical recurrenceIn: Current Opinion in Urology, Jg. 35, 2025, Nr. 5, S. 506 – 509
-
RECIP 1.0 : A Roadmap for Clinical ImplementationIn: Journal of Nuclear Medicine (JNM), Jg. 66, 2025, Nr. 5, S. 673 – 675
-
Radiopharmaceuticals in Prostate Cancer : General Considerations and Utility in Combination With EBRTIn: Seminars in Radiation Oncology, Jg. 35, 2025, Nr. 3, S. 463 – 473
-
Reply to Zhengbo Pan, Run Shi, and Zhaokai Zhou's Letter to the Editor - Re: Madeleine J. Karpinski, Kambiz Rahbar, Martin Bögemann, et al. Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study. Eur Urol. 2025;88:484–495In: European Urology, Jg. 88, 2025, Nr. 5, S. e100 – e101
-
SPARC : The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus ; A Delphi AnalysisIn: European Urology, 2025, in pressDOI (Open Access)
-
Somatostatin analogs in neuroendocrine tumors with Ki-67 index of ≥10%In: Journal of Neuroendocrinology, 2025, in pressDOI (Open Access)
-
Staging of prostate Cancer with ultra-fast PSMA-PET scans enhanced by AIIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 52, 2025, Nr. 5, S. 1658 – 1670DOI (Open Access)
-
Stellenwert der PSMA-PET/CT („prostate-specific membrane antigen positron emission tomography/computed tomography“) im Rahmen des StagingsIn: Die Urologie, Jg. 64, 2025, Nr. 3, S. 220 – 228
-
The Value of FAPI PET/CT in Cholangiocarcinoma and Pancreatic Cancer : An UpdateIn: Seminars in Nuclear Medicine, Jg. 55, 2025, Nr. 5, S. 701 – 709DOI (Open Access)
-
Thyroid Hormone Withdrawal Yields Higher ¹³¹I Absorbed Dose to Metastases Than rhTSH Stimulation in Differentiated Thyroid Cancer : Evidence from a Large ¹²⁴I PET/CT Dosimetry CohortIn: Journal of Nuclear Medicine (JNM), Jg. 66, 2025, Nr. 11, S. 1722 – 1728
-
Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2) : Results from an International Multicentre Registry StudyIn: European Urology, Jg. 88, 2025, Nr. 5, S. 484 – 495DOI (Open Access)
-
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP) : A Post Hoc Analysis from a Randomised, Open-label, Phase 2 TrialIn: European Urology Oncology, Jg. 8, 2025, Nr. 1, S. 21 – 28
-
[18F]FDG-PET/CT-based evaluation of tumor response kinetics during induction chemotherapy and concurrent radiochemotherapy in stage II - III small-cell lung cancerIn: European Journal of Nuclear Medicine and Molecular Imaging, 2025, in pressDOI (Open Access)
-
[⁶⁸Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation : A single-centre, single-arm, interventional, phase 2 trialIn: The Lancet Oncology, Jg. 26, 2025, Nr. 9, S. 1204 – 1214DOI (Open Access)
-
68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical TherapyIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 6, S. 880 – 887
-
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP StudyIn: European Urology Oncology, Jg. 7, 2024, Nr. 5, S. 1132 – 1140
-
Beyond Prostate Imaging Reporting and Data System : Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate CancerIn: The Journal of Urology, Jg. 212, 2024, Nr. 2, S. 299 – 307
-
Biodistribution and radiation dosimetry of ¹²⁴I-mIBG in adult patients with neural crest tumours and extrapolation to paediatric modelsIn: EJNMMI Physics, Jg. 11, 2024, Nr. 1, 3DOI, Online Volltext (Open Access)
-
Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRTIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 51, 2024, Nr. 3, S. 841 – 851DOI (Open Access)
-
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer : A multicentre retrospective studyIn: The Lancet Oncology, Jg. 25, 2024, Nr. 9, S. 1188 – 1201DOI (Open Access)
-
Delayed ⁶⁸Ga-FAPI-46 PET/MR imaging confirms ongoing fibroblast activation in patients after acute myocardial infarctionIn: International Journal of Cardiology (IJC) Heart & Vasculature, Jg. 50, 2024, 101340DOI (Open Access)
-
Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [⁶⁸Ga]Ga-/[¹⁸F]F-PSMA-11/-1007, [⁶⁸Ga]Ga-FAPI-46 and 2-[¹⁸F]FDG PET/CT : a pilot studyIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 52, 2024, Nr. 1, S. 342 – 353DOI (Open Access)
-
Diagnostic Accuracy of ⁶⁸Ga-FAPI Versus ¹⁸F-FDG PET in Patients with Various MalignanciesIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 3, S. 372 – 378DOI (Open Access)
-
Differences and Common Ground in ¹⁷⁷Lu-PSMA Radioligand Therapy Practice Patterns : International Survey of 95 Theranostic CentersIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 3, S. 438 – 445DOI (Open Access)
-
Dose-Response Relationship in Patients with Liver Metastases from Neuroendocrine Neoplasms Undergoing Radioembolization with ⁹⁰Y Glass MicrospheresIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 8, S. 1175 – 1180
-
FAPI PET Imaging Supports Clinical Decision Making in Academic Cardiology Practice : A Pictorial Imaging VignetteIn: JACC Cardiovascular Imaging, Jg. 17, 2024, Nr. 7, S. 811 – 823DOI (Open Access)
-
Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous TumorIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 2, S. 252 – 257DOI (Open Access)
-
Fibroblast Activation Protein-Directed Imaging Outperforms ¹⁸F-FDG PET/CT in Malignant Mesothelioma : A Prospective, Single-Center, Observational TrialIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 8, S. 1188 – 1193
-
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)In: European Urology, Jg. 86, 2024, Nr. 1, S. 52 – 60
-
Impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [⁶⁸Ga]-DOTATOC PET/MRIIn: Clinical and Translational Imaging, Jg. 12, 2024, Nr. 4, S. 441 – 448
-
Impact of ¹⁸F-FDG PET/MRI on Therapeutic Management of Women with Newly Diagnosed Breast Cancer : Results from a Prospective Double-Center TrialIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 12, S. 1855 – 1861
-
Implementation of PET/CT in radiation oncology : A patterns-of-care analysis of the German Society of Nuclear Medicine and the German Society of Radiation OncologyIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics, Jg. 200, 2024, Nr. 11, S. 931 – 941DOI (Open Access)
-
PSMA-PET follow-up to assess response in patients not receiving PSMA therapy : Is there value beyond localization of disease?In: Theranostics, Jg. 14, 2024, Nr. 9, S. 3623 – 3633DOI, Online Volltext (Open Access)
-
PSMA-PET research: addressing challenges and prospects : Authors' replyIn: The Lancet Oncology, Jg. 25, 2024, Nr. 11, e533
-
Prognostic Implications of ⁶⁸Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid TumorsIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 7, S. 1027 – 1034
-
Prostate-specific Membrane Antigen Positron Emission Tomography–detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer : An International Multicenter Retrospective StudyIn: European Urology, Jg. 85, 2024, Nr. 6, S. 511 – 516DOI (Open Access)
-
RECIP 1.0 Predicts Progression-Free Survival After [¹⁷⁷Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate CancerIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 6, S. 917 – 922
-
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)In: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 7, S. 1076 – 1079
-
Recurrent prostate cancer : combined role for MRI and PSMA-PET in ⁶⁸Ga-PSMA-11 PET/MRIIn: European Radiology, Jg. 34, 2024, Nr. 7, S. 4789 – 4800DOI (Open Access)
-
Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World DatabaseIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 1, S. 94 – 99DOI (Open Access)
-
Safety and Efficacy of Extended Therapy with [¹⁷⁷Lu]Lu-PSMA : A German Multicenter StudyIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 6, S. 909 – 916
-
Safety and Efficacy of Para-Aminohippurate Coinfusion for Renal Protection During Peptide Receptor Radiotherapy in Patients with Neuroendocrine TumorsIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 6, S. 931 – 937
-
The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma : A Comparison of Tissue, ⁶⁸Ga-FAPI-46 PET Data, and Survival DataIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 8, S. 1217 – 1223
-
Theranostics with somatostatin receptor antagonists in SCLC : Correlation of 68Ga-SSO120 PET with immunohistochemistry and survivalIn: Theranostics, Jg. 14, 2024, Nr. 14, S. 5400 – 5412DOI, Online Volltext (Open Access)
-
Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? : Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging ParametersIn: European Urology Oncology, Jg. 7, 2024, Nr. 2, S. 231 – 240
-
Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy : a retrospective multi-institutional propensity score analysisIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 51, 2024, Nr. 12, S. 3770 – 3781DOI (Open Access)
-
[⁶⁸Ga]Ga-FAPI versus 2-[¹⁸F]FDG PET/CT in patients with autoimmune thyroiditis : A case control studyIn: EJNMMI Research, Jg. 14, 2024, Nr. 1, 66DOI, Online Volltext (Open Access)
-
177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior ²²³Ra (RALU Study)In: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 12, S. 1925 – 1931DOI (Open Access)
-
18F-PSMA Cerenkov Luminescence and Flexible Autoradiography Imaging in a Prostate Cancer Mouse Model and First Results of a Radical Prostatectomy Feasibility Study in MenIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 4, S. 598 – 604DOI (Open Access)
-
68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment : An International Multicenter Prospective StudyIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 7, S. 1043 – 1048DOI (Open Access)
-
68Ga-Labeled Fibroblast Activation Protein Inhibitor (⁶⁸Ga-FAPI) PET for Pancreatic Adenocarcinoma : Data from the ⁶⁸Ga-FAPI PET Observational TrialIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 12, S. 1910 – 1917DOI (Open Access)
-
68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients : A Single-Center Retrospective StudyIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 10, S. 1540 – 1549DOI (Open Access)
-
A Retrospective Multicenter Analysis of the Incidence of Bone-Only Disease at PSMA PET/CT in Castration Resistant Prostate Cancer PatientsIn: Cancers, Jg. 15, 2023, Nr. 8, 2208DOI (Open Access)
-
A VISION Substudy of Reader Agreement on ⁶⁸Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for ¹⁷⁷Lu-PSMA-617 Radioligand TherapyIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 8, S. 1259 – 1265DOI (Open Access)
-
Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapyIn: Journal for ImmunoTherapy of Cancer, Jg. 11, 2023, Nr. 10, e007354DOI (Open Access)
-
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer, Jg. 4, 2023, Nr. 9, S. 1395DOI (Open Access)
-
Bone Metastases in Patients with Pancreatic NETs : Prevalence and PrognosisIn: Hormone and Metabolic Research, Jg. 28, 2023, Nr. 4
-
Clinical Decision Support for Axillary Lymph Node Staging in Newly Diagnosed Breast Cancer Patients Based on ¹⁸F-FDG PET/MRI and Machine LearningIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 2, S. 304 – 311DOI (Open Access)
-
Conventional Imaging, MRI and ¹⁸F-FDG PET/MRI for N and M Staging in Patients with Newly Diagnosed Breast CancerIn: Cancers, Jg. 15, 2023, Nr. 14, 3646DOI (Open Access)
-
Correction: Fully Automated, High-Dose Radiosynthesis of [18F]PARPiIn: Pharmaceuticals, Jg. 16, 2023, Nr. 7, 1024DOI (Open Access)
-
Correlation of the apparent diffusion coefficient with the standardized uptake value in meningioma of the skull plane using [68]Ga-DOTATOC PET/MRIIn: Nuclear Medicine Communications, Jg. 44, 2023, Nr. 12, S. 1106 – 1113
-
DGN-Handlungsempfehlung (S1-Leitlinie) : PSMA-Liganden-PET/CT in der Diagnostik des Prostatakarzinoms - Stand: 01/2022 - AWMF-Registernummer: 031-055In: Nuklearmedizin = Nuclear Medicine, Jg. 62, 2023, Nr. 1, S. 5 – 19
-
Demonstration of the Early Cardiac Bioavailability of a Non-Specific Cell-Targeted Peptide Using Radionuclide-Based Imaging In VivoIn: Pharmaceuticals, Jg. 16, 2023, Nr. 6, 824DOI, Online Volltext (Open Access)
-
Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate CancerIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 6, S. 869 – 872DOI (Open Access)
-
Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? : An International Multicenter Retrospective Study with Masked Independent ReadersIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 11, S. 1744 – 1747DOI (Open Access)
-
Efficacy and Safety of¹²⁴I-MIBG Dosimetry-Guided High-Activity¹³¹I-MIBG Therapy of Advanced Pheochromocytoma or NeuroblastomaIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 6, S. 885 – 891DOI (Open Access)
-
Evaluation of [⁶⁸Ga]-DOTATOC PET/MRI in Patients with Meningioma of the Subcranial and Intraorbital SpaceIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 8, S. 1185 – 1190DOI (Open Access)
-
Evaluation of thresholding methods for the quantification of [⁶⁸Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapyIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 50, 2023, Nr. 7, S. 2196 – 2209DOI (Open Access)
-
Fibroblast Activation Protein Inhibitor Theranostics : The Case for Use in SarcomaIn: PET Clinics, Jg. 18, 2023, Nr. 3, S. 361 – 367
-
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 5, S. 711 – 716DOI (Open Access)
-
Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel ToolIn: European Urology Oncology, Jg. 6, 2023, Nr. 6, S. 543 – 552
-
Incidental Detection of a Tenosynovial Giant Cell Tumor of the Thigh on [⁶⁸Ga]Ga-FAPI PET/CT : Presentation of an Unusual CaseIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 7, S. 1162 – 1163DOI (Open Access)
-
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer, Jg. 4, 2023, Nr. 9, S. 1292 – 1308DOI (Open Access)
-
Intraoperative Molecular Positron Emission Tomography Imaging for Intraoperative Assessment of Radical Prostatectomy SpecimensIn: European Urology Open Science, Jg. 54, 2023, S. 28 – 32DOI (Open Access)
-
Is There a Role of Artificial Intelligence in Preclinical Imaging?In: Seminars in Nuclear Medicine, Jg. 53, 2023, Nr. 5, S. 687 – 693
-
Is ¹⁸F-FDG PET Needed to Assess ¹⁷⁷Lu-PSMA Therapy Eligibility? : A VISION-like, Single-Center AnalysisIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 5, S. 731 – 737DOI (Open Access)
-
Joint EANM/SNMMI procedure guideline for the use of ¹⁷⁷Lu-labeled PSMA-targeted radioligand-therapy (¹⁷⁷Lu-PSMA-RLT)In: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 50, 2023, Nr. 9, S. 2830 – 2845DOI (Open Access)
-
Lesion Quantification Accuracy of Digital 90Y PET Imaging in the Context of Dosimetry in Systemic FAPI Radionuclide TherapyIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 2, S. 329 – 336DOI (Open Access)
-
Molecular Imaging of Lymphoma : Future Directions and PerspectivesIn: Seminars in Nuclear Medicine, Jg. 53, 2023, Nr. 3, S. 449 – 456
-
Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid CarcinomaIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 12, S. 1865 – 1868DOI (Open Access)
-
Novel ⁶⁸Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine-Related PitfallsIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 3, S. 368 – 371DOI (Open Access)
-
Oncologic Staging with ⁶⁸Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than ¹⁸F-FDG PET/CTIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 12, S. 1906 – 1909DOI (Open Access)
-
PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [¹⁷⁷Lu]PSMA Radioligand Therapy : An International Multicenter Retrospective StudyIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 7, S. 1024 – 1029DOI (Open Access)
-
PSMA PET/CT : Joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0In: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 50, 2023, Nr. 5, S. 1466 – 1486DOI (Open Access)
-
PSMA-Directed Imaging and Therapy of Salivary Gland Tumors : A Single-Center Retrospective StudyIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 3, S. 372 – 378DOI (Open Access)
-
Predictive value of highly sensitive basal versus stimulated thyroglobulin measurement in long-term follow-up of thyroid cancerIn: Endocrine Connections, Jg. 12, 2023, Nr. 2, e220312DOI, Online Volltext (Open Access)
-
Presurgical ⁶⁸Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment : A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging TrialIn: European Urology, Jg. 84, 2023, Nr. 6, S. 588 – 596
-
Prostate-specific Membrane Antigen Reporting and Data System Version 2.0In: European Urology, Jg. 84, 2023, Nr. 5, S. 491 – 502DOI (Open Access)
-
Quantification performance of silicon photomultiplier-based PET for small ¹⁸F-, ⁶⁸Ga- and ¹²⁴I-avid lesions in the context of radionuclide therapy planningIn: Physica Medica: European Journal of Medical Physics, Jg. 114, 2023, 103149DOI (Open Access)
-
Rabbit fever : granulomatous inflammation by Francisella tularensis mimics lung cancer in dual tracer ¹⁸FDG and ⁶⁸Ga-FAPI PET/CTIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 50, 2023, Nr. 8, S. 2567 – 2569DOI (Open Access)
-
Radioiodine Ablation of Thyroid Remnants in Patients with Graves' OrbitopathyIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 4, S. 561 – 566DOI (Open Access)
-
Reduction of emission time for [68Ga]Ga-PSMA PET/CT using the digital biograph vision : A phantom studyIn: The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Jg. 67, 2023, Nr. 1, S. 57 – 68
-
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate CancerIn: Radiology, Jg. 308, 2023, Nr. 1, e222148DOI, Online Volltext (Open Access)
-
SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET : Imaging Neuroendocrine TumorsIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 2, S. 204 – 210DOI (Open Access)
-
SUVmₐₓ Above 20 in ¹⁸F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown PrimaryIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 8, S. 1191 – 1194DOI (Open Access)
-
Safety and Survival Outcomes of ¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior ²²³Ra treatment : The RALU StudyIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 4, S. 574 – 578DOI (Open Access)
-
Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective studyIn: Radiotherapy and Oncology (The Green Journal), Jg. 184, 2023, 109678DOI (Open Access)
-
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)In: European Urology, Jg. 83, 2023, Nr. 5, S. 405 – 412DOI (Open Access)
-
Standardized PSMA-PET Imaging of Advanced Prostate CancerIn: Seminars in Nuclear Medicine, Jg. 54, 2023, Nr. 1, S. 60 – 68
-
Superior Tumor Detection for ⁶⁸Ga-FAPI-46 Versus ¹⁸F-FDG PET/CT and Conventional CT in Patients with CholangiocarcinomaIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 7, S. 1049 – 1055DOI (Open Access)
-
Unspecific ¹⁸F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate CancerIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 5, S. 738 – 743DOI (Open Access)
-
Using PSMA imaging for prognostication in localized and advanced prostate cancerIn: Nature Reviews Urology, Jg. 20, 2023, Nr. 1, S. 23 – 47
-
Voxel-Based Dosimetry Predicts Hepatotoxicity in Hepatocellular Carcinoma Patients Undergoing Radioembolization with ⁹⁰Y Glass MicrospheresIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 7, S. 1102 – 1108DOI (Open Access)
-
What Role Does PET/MRI Play in Musculoskeletal Disorders?In: Seminars in Nuclear Medicine, Jg. 55, 2023, Nr. 2, S. 277 – 289
-
[¹⁸F]FDG PET/MRI in children suffering from lymphoma : does MRI contrast media make a difference?In: European Radiology, Jg. 33, 2023, Nr. 11, S. 8366 – 8375DOI (Open Access)
-
68Ga-FAPI as a Diagnostic Tool in Sarcoma : Data from the 68Ga-FAPI PET Prospective Observational TrialIn: Journal of Nuclear Medicine (JNM), Jg. 63, 2022, Nr. 1, S. 89 – 95DOI (Open Access)
-
A Role for PET/CT in response assessment of malignant pleural mesotheliomaIn: Seminars in Nuclear Medicine, Jg. 52, 2022, Nr. 6, S. 816 – 823
-
A Role of PET/MR in Breast Cancer?In: Seminars in Nuclear Medicine, Jg. 52, 2022, Nr. 5, S. 611 – 618
-
Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in MiceIn: Journal of Nuclear Medicine (JNM), Jg. 63, 2022, Nr. 9, S. 1357 – 1363DOI, Online Volltext (Open Access)
-
Comparison of nodal staging between CT, MRI, and [¹⁸F]-FDG PET/MRI in patients with newly diagnosed breast cancerIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 49, 2022, S. 992 – 1001DOI (Open Access)
-
Correction to : Value of PET imaging for radiation therapyIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics, Jg. 198, 2022, Nr. 1, S. 80 – 82DOI (Open Access)
-
Diagnostic Performance of ¹²⁴I-Metaiodobenzylguanidine PET/CT in Patients with PheochromocytomaIn: Journal of Nuclear Medicine (JNM), Jg. 63, 2022, Nr. 6, S. 869 – 874DOI (Open Access)
-
Effects of Anti-Tumor Necrosis Factor Therapy on Osteoblastic Activity at Sites of Inflammatory and Structural Lesions in Radiographic Axial Spondyloarthritis : A Prospective Proof-of-Concept Study Using Positron Emission Tomography/Magnetic Resonance Imaging of the Sacroiliac Joints and SpineIn: Arthritis & Rheumatology, Jg. 74, 2022, Nr. 9, S. 1497 – 1505DOI (Open Access)
-
Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI) : A Single-Center Prospective Two-Arm StudyIn: Clinical Cancer Research, Jg. 28, 2022, Nr. 19, S. 4194 – 4202DOI (Open Access)
-
FDG-PET Positivity and Overall Survival in Renal Cell CarcinomaIn: JAMA Network Open, Jg. 5, 2022, Nr. 11, e2242289DOI, Online Volltext (Open Access)
-
First experiences with dynamic renal [⁶⁸Ga]Ga-DOTA PET/CT : A comparison to renal scintigraphy and compartmental modelling to non-invasively estimate the glomerular filtration rateIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 49, 2022, Nr. 10, S. 3373 – 3386DOI (Open Access)
-
Free-breathing 3D Stack of Stars GRE (StarVIBE) sequence for detecting pulmonary nodules in 18F-FDG PET/MRIIn: EJNMMI Physics, Jg. 9, 2022, Nr. 1, 11DOI (Open Access)
-
Fully Automated, High-Dose Radiosynthesis of [18F]PARPiIn: Pharmaceuticals, Jg. 15, 2022, Nr. 7, 865DOI, Online Volltext (Open Access)
-
Improved production of ⁶⁸Ga-Pentixafor using cartridge mediated cation exchange purificationIn: Applied Radiation and Isotopes, Jg. 189, 2022, 110447
-
Initial Clinical Experience with ⁹⁰Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors : A Case Series of 9 PatientsIn: Journal of Nuclear Medicine (JNM), Jg. 63, 2022, Nr. 5, S. 727 – 734DOI (Open Access)
-
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification : A post-hoc analysis of the PETAL trialIn: Leukemia, Jg. 36, 2022, Nr. 12, S. 2845 – 2852DOI (Open Access)
-
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT : comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteriaIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 49, 2022, Nr. 12, S. 4271 – 4281DOI (Open Access)
-
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaIn: Cancer Imaging, Jg. 22, 2022, Nr. 1DOI, Online Volltext (Open Access)
-
Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After ProstatectomyIn: International Journal of Radiation Oncology, Biology, Physics, Jg. 113, 2022, Nr. 5, S. 1015 – 1024
-
Multiparametric¹⁸F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast CancerIn: Cancers, Jg. 14, 2022, Nr. 7, 1727DOI (Open Access)
-
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0) : An International Multicenter StudyIn: Journal of Nuclear Medicine (JNM), Jg. 63, 2022, Nr. 11, S. 1651 – 1658DOI (Open Access)
-
Onkologische Theranostik in der NuklearmedizinIn: Die Radiologie, Jg. 62, 2022, Nr. 10, S. 875 – 884
-
Onkologische Theranostik in der NuklearmedizinIn: Die Onkologie, Jg. 28, 2022, Nr. 7, S. 612 – 622
-
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups : An International Multicenter StudyIn: Journal of Nuclear Medicine (JNM), Jg. 63, 2022, Nr. 1, S. 76 – 80DOI (Open Access)
-
PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients : A Multicenter Retrospective StudyIn: Cancers, Jg. 14, 2022, Nr. 22, 5680DOI (Open Access)
-
Phantom-based acquisition time and image reconstruction parameter optimisation for oncologic FDG PET/CT examinations using a digital systemIn: BMC Cancer, Jg. 22, 2022, Nr. 1, 899DOI, Online Volltext (Open Access)
-
Pitfalls and Common Findings in ⁶⁸Ga-FAPI PET : A Pictorial AnalysisIn: Journal of Nuclear Medicine (JNM), Jg. 63, 2022, Nr. 6, S. 890 – 896DOI (Open Access)
-
Prostataspezifische Membranantigen-Positronenemissionstomographie (PSMA-PET) für Urologen : Wann und welcher Tracer?In: Der Urologe, Jg. 61, 2022, Nr. 4, S. 384 – 391DOI (Open Access)
-
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer : A Retrospective Single-center StudyIn: European Urology Oncology, Jg. 5, 2022, Nr. 5, S. 544 – 552
-
Radiation Protection and Occupational Exposure on ⁶⁸Ga-PSMA-11-Based Cerenkov Luminescence Imaging Procedures in Robot-Assisted ProstatectomyIn: Journal of Nuclear Medicine (JNM), Jg. 63, 2022, Nr. 9, S. 1349 – 1356DOI (Open Access)
-
Repeatability of ⁶⁸Ga-PSMA-HBED-CC PET/CT-Derived Total Molecular Tumor VolumeIn: Journal of Nuclear Medicine (JNM), Jg. 63, 2022, Nr. 5, S. 746 – 753DOI (Open Access)
-
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell CarcinomaIn: Journal of Nuclear Medicine (JNM), Jg. 63, 2022, Nr. 3, S. 396 – 398DOI (Open Access)
-
Response to letter to the editorIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 49, 2022, Nr. 10, S. 3336 – 3339DOI (Open Access)
-
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesIn: Clinical Cancer Research, Jg. 28, 2022, Nr. 19, S. 4346 – 4353DOI (Open Access)
-
Tumor Sink Effect in ⁶⁸Ga-PSMA-11 PET : Myth or Reality?In: Journal of Nuclear Medicine (JNM), Jg. 63, 2022, Nr. 2, S. 226 – 232DOI (Open Access)
-
¹⁸F-PSMA-11 Versus ⁶⁸Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer : A Prospective Double-blind Randomised Cross-over TrialIn: European Urology, Jg. 82, 2022, Nr. 5, S. 501 – 509
-
⁶⁸Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomasIn: Scientific Reports, Jg. 12, 2022, Nr. 1, 16261DOI, Online Volltext (Open Access)
-
Analysis of risk factors and prognosis in differentiated thyroid cancer with focus on minimal extrathyroidal extensionIn: BMC Endocrine Disorders, Jg. 21, 2021, Nr. 1, 161DOI, Online Volltext (Open Access)
-
Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodelingIn: Journal of Nuclear Cardiology, Jg. 28, 2021, Nr. 3, S. 812 – 821DOI (Open Access)
-
Comparing lesion detection efficacy and image quality across different PET system generations to optimize the iodine-124 PET protocol for recurrent thyroid cancerIn: EJNMMI Physics, Jg. 8, 2021, Nr. 1, 14DOI, Online Volltext (Open Access)
-
Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapyIn: Journal for ImmunoTherapy of Cancer, Jg. 9, 2021, Nr. 3, S. 002262DOI, Online Volltext (Open Access)
-
Determining the Axillary Nodal Status with 4 Current Imaging Modalities, Including 18F-FDG PET/MRI, in Newly Diagnosed Breast Cancer : A Comparative Study Using Histopathology as the Reference StandardIn: Journal of Nuclear Medicine (JNM), Jg. 62, 2021, Nr. 12, S. 1677 – 1683DOI (Open Access)
-
Diagnostic Accuracy of ⁶⁸Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection : A Multicenter Prospective Phase 3 Imaging TrialIn: JAMA Oncology, Jg. 7, 2021, Nr. 11, S. 1635 – 1642
-
Digital and respiratory-gated FDG PET/CT for characterization of lung lesionsIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 48, 2021, Nr. Suppl. 1, S. 83
-
Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancerIn: Nuclear Medicine and Biology, Jg. 96-97, 2021, S. 101 – 111DOI (Open Access)
-
Enzalutamide enhances psma expression of psma-low prostate cancerIn: International Journal of Molecular Sciences (IJMS), Jg. 22, 2021, Nr. 14, 7431DOI, Online Volltext (Open Access)
-
Equivalent tumor detection for early and late FAPI-46 PET acquisitionIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 48, 2021, Nr. 10, S. 3221 – 3227DOI (Open Access)
-
Evaluation of [⁶⁸Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph visionIn: EJNMMI Research, Jg. 11, 2021, Nr. 1, S. 21DOI, Online Volltext (Open Access)
-
Evaluation of ¹⁸F-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph visionIn: BMC Cancer, Jg. 21, 2021, Nr. 1, 62DOI, Online Volltext (Open Access)
-
False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trialIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 48, 2021, Nr. 2, S. 501 – 508DOI (Open Access)
-
Head-to-head intra-individual comparison of biodistribution and tumor uptake of ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT in cancer patientsIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 48, 2021, Nr. 13, S. 4377 – 4385DOI (Open Access)
-
Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging : A Multicenter Retrospective StudyIn: Journal of Nuclear Medicine (JNM), Jg. 62, 2021, Nr. 5, S. 675 – 678DOI (Open Access)
-
Imaging Inflammation with Positron Emission TomographyIn: Biomedicines, Jg. 9, 2021, Nr. 2, S. 212DOI, Online Volltext (Open Access)
-
Just another “Clever Hans”? : Neural networks and FDG PET-CT to predict the outcome of patients with breast cancerIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 48, 2021, Nr. 10, S. 3141 – 3150DOI (Open Access)
-
Lung uptake detected by ⁶⁸Ga-PSMA-11 PET/CT in prostate cancer patients with SARS-CoV-2 : a case seriesIn: American Journal of Nuclear Medicine and Molecular Imaging, Jg. 11, 2021, Nr. 4, S. 300 – 306Online Volltext (Open Access)
-
Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate CancerIn: Journal of Nuclear Medicine (JNM), Jg. 62, 2021, Nr. 7, S. 989 – 995DOI (Open Access)
-
N-staging in large cell neuroendocrine carcinoma of the lung : diagnostic value of [¹⁸F]FDG PET/CT compared to the histopathology reference standardIn: EJNMMI Research, Jg. 11, 2021, Nr. 1, 68DOI, Online Volltext (Open Access)
-
Nomograms to predict outcomes after ¹⁷⁷Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer : An international, multicentre, retrospective studyIn: The Lancet Oncology, Jg. 22, 2021, Nr. 8, S. 1115 – 1125DOI (Open Access)
-
Oldies (but Goldies) : Die Peritonealszintigrafie bei PeritonealdialyseIn: Nuklearmedizin = Nuclear Medicine, Jg. 60, 2021, Nr. 06, S. 450 – 453
-
PET/CT versus PET/MRT bei Kopf-Hals-TumorenIn: TumorDiagnostik & Therapie, Jg. 42, 2021, Nr. 5, S. 354 – 360
-
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysisIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 48, 2021, Nr. 4, S. 1200 – 1210DOI (Open Access)
-
PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of diseaseIn: Journal of Nuclear Medicine (JNM), Jg. 62, 2021, Nr. 12, S. 1747 – 1750DOI (Open Access)
-
PSMA-ligand PET for early castration-resistant prostate cancer : a retrospective single-center studyIn: Journal of Nuclear Medicine (JNM), Jg. 62, 2021, Nr. 1, S. 88 – 91DOI (Open Access)
-
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT] : study protocolIn: BMC Cancer, Jg. 21, 2021, 512DOI (Open Access)
-
Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patientsIn: European Radiology, Jg. 31, 2021, Nr. 11, S. 8714 – 8724DOI (Open Access)
-
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC) : efficacy results of the UCLA cohortIn: Journal of Nuclear Medicine (JNM), Jg. 62, 2021, Nr. 10, S. 1440 – 1446DOI, Online Volltext (Open Access)
-
Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imaging : Utilization of a short-pass filter to reduce technical pitfallsIn: Translational Andrology and Urology, Jg. 10, 2021, Nr. 10, S. 3972 – 3985DOI (Open Access)
-
Prostate-specific Membrane Antigen–based Imaging of Castration-resistant Prostate CancerIn: European Urology Focus, Jg. 7, 2021, Nr. 2, S. 279 – 287
-
Prostate-specific membrane antigen PET in prostate cancerIn: Radiology, Jg. 299, 2021, Nr. 2, S. 248 – 260
-
Reply: The Importance of an Adequate Surgical Template During Salvage Lymph Node Dissection for Node-Recurrent Prostate CancerIn: Journal of Nuclear Medicine (JNM), Jg. 62, 2021, Nr. 7, S. 1022DOI (Open Access)
-
Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617 : Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)In: Journal of Nuclear Medicine (JNM), Jg. 62, 2021, Nr. 10, S. 1447 – 1456DOI, Online Volltext (Open Access)
-
Silicon-photomultiplier-based PET/CT reduces the minimum detectable activity of iodine-124In: Scientific Reports, Jg. 11, 2021, Nr. 1, 17477DOI, Online Volltext (Open Access)
-
Theranostics in oncology : What radiologists want to knowIn: European Journal of Radiology, Jg. 142, 2021, 109875
-
Update from PSMA-SRT Trial NCT03582774 : A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical OutcomeIn: European Urology Focus, Jg. 7, 2021, Nr. 2, S. 238 – 240DOI, Online Volltext (Open Access)
-
Value of PET imaging for radiation therapyIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics, Jg. 179, 2021, Nr. 9, S. 757 – 779DOI (Open Access)
-
Value of PET imaging for radiation therapyIn: Nuklearmedizin = Nuclear Medicine, Jg. 60, 2021, Nr. 5, S. 326 – 343DOI (Open Access)
-
Visualization of Fibroblast Activation After Myocardial Infarction Using 68Ga-FAPI PETIn: Clinical Nuclear Medicine, Jg. 46, 2021, Nr. 10, S. 807 – 813
-
Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant MesotheliomaIn: Journal of Nuclear Medicine (JNM), Jg. 62, 2021, Nr. 2, S. 191 – 194DOI (Open Access)
-
[18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase InhibitorsIn: Oncology Research and Treatment, Jg. 44, 2021, Nr. 7-8, S. 400 – 407DOI (Open Access)
-
[⁶⁸Ga]Ga-PSMA-11 PET/CT improves tumor detection and impacts management in patients with hepatocellular carcinomaIn: Journal of Nuclear Medicine (JNM), Jg. 62, 2021, Nr. 9, S. 1235 – 1241DOI (Open Access)
-
Assessment of Suspected Malignancy or Infection in Immunocompromised Patients After Solid Organ Transplantation by [¹⁸F]FDG PET/CT and [¹⁸F]FDG PET/MRIIn: Nuclear Medicine and Molecular Imaging, Jg. 54, 2020, Nr. 4, S. 183 – 191DOI, Online Volltext (Open Access)
-
Assessment of right ventricular sympathetic dysfunction in patients with arrhythmogenic right ventricular cardiomyopathy : An ¹²³I-metaiodobenzylguanidine SPECT/CT studyIn: Journal of Nuclear Cardiology, Jg. 27, 2020, Nr. 6, S. 2402 – 2409DOI (Open Access)
-
Can the injected dose be reduced in ⁶⁸Ga-PSMA-11 PET/CT while maintaining high image quality for lesion detection?In: Journal of Nuclear Medicine (JNM), Jg. 61, 2020, Nr. 2, S. 189 – 193DOI (Open Access)
-
Efficacy and Safety of ¹⁷⁷Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement : A Multicenter Retrospective StudyIn: European Urology, Jg. 78, 2020, Nr. 2, S. 148 – 154
-
First-in-man intraoperative Cerenkov luminescence imaging for oligometastatic prostate cancer using ⁶⁸Ga-PSMA-11In: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 47, 2020, Nr. 13, S. 3194 – 3195
-
Imaging inflammation after myocardial infarction : implications for prognosis and therapeutic guidanceIn: The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Jg. 64, 2020, Nr. 1, S. 35 – 50
-
Impact of 68Ga-PSMA-11 PET on the Management of recurrent Prostate Cancer in a Prospective Single-Arm Clinical TrialIn: Journal of Nuclear Medicine (JNM), Jg. 61, 2020, Nr. 12, S. 1793 – 1799DOI (Open Access)
-
Impact of ⁶⁸Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings : A Prospective Single-Center StudyIn: Journal of Nuclear Medicine (JNM), Jg. 61, 2020, Nr. 8, S. 1153 – 1160DOI (Open Access)
-
In vivo biodistribution of calcium phosphate nanoparticles after intravascular, intramuscular, intratumoral, and soft tissue administration in mice investigated by small animal PET/CTIn: Acta Biomaterialia, Jg. 109, 2020, S. 244 – 253
-
Intraoperative 68Gallium-PSMA Cerenkov Luminescence Imaging for surgical margins in radical prostatectomy : A feasibility studyIn: Journal of Nuclear Medicine (JNM), Jg. 61, 2020, Nr. 10, S. 1500 – 1506DOI, Online Volltext (Open Access)
-
Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PETIn: Journal of Nuclear Medicine (JNM), Jg. 61, 2020, Nr. 7, S. 1037 – 1042DOI, Online Volltext (Open Access)
-
Neuroendokrine Neoplasien des VerdauungstraktsIn: Best Practice Onkologie, Jg. 15, 2020, Nr. 7-8, S. 320 – 333
-
Outcome after 68ga-psma-11 versus choline pet-based salvage radiotherapy in patients with biochemical recurrence of prostate cancer : A matched-pair analysisIn: Cancers, Jg. 12, 2020, Nr. 11, S. 3395DOI (Open Access)
-
PSMA-positive nodal recurrence in prostate cancerIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics, Jg. 196, 2020, Nr. 7, S. 637 – 646DOI (Open Access)
-
Prospective evaluation of whole-body MRI and ¹⁸F-FDG PET/MRI in N and M staging of primary breast cancer patientsIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 47, 2020, Nr. 12, S. 2816 – 2825DOI (Open Access)
-
Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrenceIn: Current Opinion in Urology, Jg. 30, 2020, Nr. 5, S. 635 – 640
-
Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumorsIn: Nuclear Medicine Communications, Jg. 41, 2020, Nr. 4, S. 363 – 369
-
Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from ⁶⁸Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficientIn: BMC Cancer, Jg. 20, 2020, Nr. 1, 326DOI, Online Volltext (Open Access)
-
Whole-Body Integrated [⁶⁸Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer : Comparison with Whole-Body PET/CT as the Standard of ReferenceIn: Molecular Imaging and Biology, Jg. 22, 2020, Nr. 3, S. 788 – 796
-
¹⁸F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitisIn: PLoS ONE, Jg. 15, 2020, Nr. 1, S. e0227906DOI, Online Volltext (Open Access)
-
18F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue SarcomasIn: Journal of Nuclear Medicine (JNM), Jg. 60, 2019, Nr. 11, S. 1537 – 1542DOI (Open Access)
-
Assessment of ⁶⁸Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer : A Prospective Single-Arm Clinical TrialIn: JAMA Oncology, Jg. 5, 2019, Nr. 6, S. 856 – 863DOI (Open Access)
-
Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planningIn: BMC Cancer, Jg. 19, 2019, 97DOI (Open Access)
-
EANM procedure guidelines for radionuclide therapy with ¹⁷⁷Lu-labelled PSMA-ligands (¹⁷⁷Lu-PSMA-RLT)In: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 46, 2019, Nr. 12, S. 2536 – 2544
-
Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective StudyIn: The Journal of Urology, Jg. 202, 2019, Nr. 6, S. 1174 – 1181
-
Impact of 68Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT : A Retrospective AnalysisIn: Journal of Nuclear Medicine (JNM), Jg. 60, 2019, Nr. 7, S. 963 – 970DOI (Open Access)
-
Improving ⁶⁸Ga-PSMA PET/MRI of the prostate with unrenormalized absolute scatter correctionIn: Journal of Nuclear Medicine (JNM), Jg. 60, 2019, Nr. 11, S. 1642 – 1648DOI (Open Access)
-
Meta-analysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by HistopathologyIn: Journal of Nuclear Medicine (JNM), Jg. 60, 2019, Nr. 6, S. 786 – 793DOI (Open Access)
-
Molecular Imaging for Primary Staging of Prostate CancerIn: Seminars in Nuclear Medicine, Jg. 49, 2019, Nr. 4, S. 271 – 279
-
Outcome after PSMA PET/CT–based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy : A 2-institution retrospective analysisIn: Journal of Nuclear Medicine (JNM), Jg. 60, 2019, Nr. 2, S. 227 – 233DOI (Open Access)
-
Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancerIn: Clinical Cancer Research, Jg. 25, 2019, Nr. 24, S. 7448 – 7454DOI (Open Access)
-
Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]In: BMC Cancer, Jg. 19, 2019, 18DOI (Open Access)
-
Salvage PRRT with ¹⁷⁷Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET) : Dosimetry, toxicity, efficacy, and survivalIn: BMC Cancer, Jg. 19, 2019, Nr. 1, S. 788DOI (Open Access)
-
Theranostics for Advanced Prostate Cancer : Current Indications and Future DevelopmentsIn: European Urology Oncology, Jg. 2, 2019, Nr. 2, S. 152 – 162
-
Theranostik von soliden Tumoren : Renaissance eines alten KonzeptsIn: Best Practice Onkologie, Jg. 14, 2019, Nr. 12, S. 526 – 534
-
What is the best PET target for early biochemical recurrence of prostate cancer? : Authors’ replyIn: The Lancet Oncology, Jg. 20, 2019, Nr. 11, S. e609 – e610
-
¹⁸F-fluciclovine PET-CT and ⁶⁸Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy : a prospective, single-centre, single-arm, comparative imaging trialIn: The Lancet Oncology, Jg. 20, 2019, Nr. 9, S. 1286 – 1294DOI, Online Volltext (Open Access)
-
Comparison of ⁶⁸Ga-PSMA-11 and ¹⁸F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrenceIn: Journal of Nuclear Medicine (JNM), Jg. 59, 2018, Nr. 5, S. 789 – 794DOI (Open Access)
-
Detection Threshold and Reproducibility of ⁶⁸Ga-PSMA11 PET/CT in a Mouse Model of Prostate CancerIn: Journal of Nuclear Medicine (JNM), Jg. 59, 2018, Nr. 9, S. 1392 – 1397DOI (Open Access)
-
Ergebnisse der LuPSMA-Studie zeigen hohe Ansprechraten mit geringer Toxizität und SchmerzlinderungIn: Der Urologe, Jg. 57, 2018, Nr. 12, S. 1494 – 1495
-
Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI : Current and future applicationsIn: American Journal of Roentgenology (AJR online), Jg. 211, 2018, Nr. 2, S. 286 – 294DOI, Online Volltext (Open Access)
-
Impact of Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical RecurrenceIn: Journal of Nuclear Medicine (JNM), Jg. 59, 2018, Nr. 3, S. 434 – 441DOI (Open Access)
-
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working groupIn: The Prostate, Jg. 78, 2018, Nr. 11, S. 775 – 789DOI (Open Access)
-
Potential impact of ⁶⁸Ga-PSMA-11 PET/CT on the planning of definitive radiation therapy for prostate cancerIn: Journal of Nuclear Medicine (JNM), Jg. 59, 2018, Nr. 11, S. 1714 – 1721DOI (Open Access)
-
Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancerIn: EJNMMI Research, Jg. 8, 2018, Nr. 1, 96DOI (Open Access)
-
Prostate cancer molecular imaging standardized evaluation (PROMISE) : Proposed miTNM classification for the interpretation of PSMA-ligand PET/CTIn: Journal of Nuclear Medicine (JNM), Jg. 59, 2018, Nr. 3, S. 469 – 478DOI (Open Access)
-
Reply: Comparison of Ga-PSMA-11 and F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective Trial Is on Its WayIn: Journal of Nuclear Medicine (JNM), Jg. 59, 2018, Nr. 5, S. 861DOI (Open Access)
-
⁶⁸Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL : Impact on salvage radiotherapy planningIn: Journal of Nuclear Medicine (JNM), Jg. 59, 2018, Nr. 2, S. 230 – 237DOI (Open Access)
-
177Lu-PSMA Radioligand Therapy for Prostate CancerIn: Journal of Nuclear Medicine (JNM), Jg. 58, 2017, Nr. 8, S. 1196 – 1200DOI (Open Access)
-
68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment : Results of a Prospective Study on 50 PatientsIn: Journal of Nuclear Medicine (JNM), Jg. 58, 2017, Nr. 2, S. 307 – 311DOI, Online Volltext (Open Access)
-
68Ga-PSMA PET/CT : Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0In: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 44, 2017, Nr. 6, S. 1014 – 1024
-
68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments : An International Multicenter Prospective StudyIn: Journal of Nuclear Medicine (JNM), Jg. 58, 2017, Nr. 10, S. 1617 – 1623
-
A PET for All Seasons : 18F-Fluorodeoxyglucose to Characterize Inflammation and Malignancy in Retroperitoneal Fibrosis?In: European Urology, Jg. 71, 2017, Nr. 6, S. 934 – 935
-
Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate CancerIn: Journal of Nuclear Medicine (JNM), Jg. 58, 2017, Nr. 11, S. 1786 – 1792DOI (Open Access)
-
Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are ImplementedIn: Journal of Nuclear Medicine (JNM), Jg. 58, 2017, Nr. 11, S. 1793 – 1796DOI, Online Volltext (Open Access)
-
NTR Is the New SSTR? : Perspective for Neurotensin Receptor 1 (NTR)-Directed TheranosticsIn: Journal of Nuclear Medicine (JNM), Jg. 58, 2017, Nr. 6, S. 934 – 935
-
PSMA ligands for PET imaging of prostate cancerIn: Journal of Nuclear Medicine (JNM), Jg. 58, 2017, Nr. 10, S. 1545 – 1552
-
PSMA ligands in prostate cancer – Probe optimization and theranostic applicationsIn: Methods: A Companion to Methods in Enzymology, Jg. 130, 2017, S. 42 – 50
-
Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancerIn: OncoTarget, Jg. 8, 2017, Nr. 2, S. 3581 – 3590DOI (Open Access)
-
Prostate-specific membrane antigen ligands for imaging and therapyIn: Journal of Nuclear Medicine (JNM), Jg. 58, 2017, Nr. Suppl. 2, S. 67S – 76S
-
Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer : Absorbed Dose in Normal Organs and Tumor LesionsIn: Journal of Nuclear Medicine (JNM), Jg. 58, 2017, Nr. 3, S. 445 – 450DOI (Open Access)
-
The impact of somatostatin receptor-directed PET/CT on the management of patients with neuroendocrine tumor : A systematic review and meta-analysisIn: Journal of Nuclear Medicine (JNM), Jg. 58, 2017, Nr. 5, S. 756 – 761DOI (Open Access)
-
(68)Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging : The New Kid on the Block-Early or Too Early to Draw Conclusions?In: European Urology, Jg. 70, 2016, Nr. 6, S. 938 – 940
-
Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancerIn: Expert Review of Molecular Diagnostics, Jg. 16, 2016, Nr. 11, S. 1177 – 1188
-
Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker : Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate CancerIn: European Urology. Amsterdam: Elsevier, Jg. 87, 2025, Nr. 3, S. 275 – 277
-
The Co-IMPACT Consortium : Integrating Prostate-specific Membrane Antigen Positron Emission Tomography and Radiotherapy in Prostate Cancer CareIn: European Urology. Amsterdam: Elsevier, Jg. 87, 2025, Nr. 4, S. 379 – 384
-
Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit : A Roadmap for Research and Clinical Application in Nonmetastatic Prostate CancerIn: European Urology. Amsterdam: Elsevier, Jg. 86, 2024, Nr. 2, S. 81 – 87
-
May the Nuclear Medicine be with you! : Neuroendocrine tumours and the return of nuclear medicineIn: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 25, 2024, Nr. 1, S. 3 – 8DOI (Open Access)
-
The novel PROMISE framework for PSMA-PET reporting : Ready for the clinical routine?In: Clinical and Translational Imaging. Berlin: Springer, Jg. 12, 2024, Nr. 1, S. 1 – 3DOI (Open Access)
-
2021: the year [¹⁷⁷Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo GerickeIn: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, 2021DOI, Online Volltext (Open Access)
-
Nuclear Medicine Beyond VISIONIn: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 62, 2021, Nr. 7, S. 916 – 917DOI (Open Access)
-
We Can Make a Difference : Investigator-driven Prostate-specific Membrane Antigen Radiotheranostics for Prostate CancerIn: European Urology Focus. Amsterdam: Elsevier, Jg. 7, 2021, Nr. 2, S. 227 – 228
-
Oliver Sartor talks with Thomas A. Hope, Jeremie Calais and Wolfgang P. Fendler about FDA Approval of PSMAIn: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 62, 2021, Nr. 2, S. 146 – 148DOI (Open Access)
-
68Ga-FAPI-46 PET for Imaging of FAP-expressing Cancer : Results from a Prospective, Single-Arm, Interventional Phase 2 Clinical TrialIn: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 66, 2025, Nr. Supplement 1, 251524Online Volltext (Open Access)
-
Clinical value of [68Ga]Ga-FAPI-46 PET in Comparison to [18F]FDG PET in Triple-negative Breast Cancer and Possible Theranostic ApplicationsIn: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 66, 2025, Nr. Supplement 1, 251520Online Volltext (Open Access)
-
Three-tier risk stratification of prostate cancer by PSMA-PET PROMISE (PPP2) : Results from an international multi-centre registry studyIn: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 66, 2025, Nr. Supplement 1, 251292Online Volltext (Open Access)
-
Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) therapy in patients (pts) with prior Radium-223 (223Ra)
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Suppl. 2, S. S983 – S984 -
PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Suppl. 2, S. S971 -
Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment : A surrogate of pelvic lymph node dissection? ; Follow-up analysis of a multicenter prospective phase 3 imaging trial
2024 ASCO Genitourinary Cancers Symposium, January 25–27, 2024, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 42, 2024, Nr. Supplement 4, S. 285 – 285 -
Prognostic PSMA-PET PROMISE nomograms for patients with prostate cancerIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 42, 2024, Nr. Suppl. 16, 5016
-
The Role Of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma : A Comparison Of Tissue, 68ga-Fapi-46 Positron Emission Tomography and Survival Data
29th Annual Meeting and Education Day of the Society for Neuro-Oncology, November 21-24, 2024, Houston, TX, USA,In: Neuro-Oncology. Oxford: Oxford University Press, Jg. 26, 2024, Nr. Supplement 8, S. viii196 – viii197 -
The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma : A Comparison of Tissue, 68GA-FAPI-46 Positron Emission Tomography and Survival Data
19th Meeting of the European Association of Neuro-Oncology (EANO 2024), October 17-20, 2024, Glasgow, UK,In: Neuro-Oncology. Oxford: Oxford University Press, Jg. 26, 2024, Nr. Supplement 5, S. v25 – v25 -
68Ga-FAPI-46 PET for imaging of FAP expressing cancer - interim findings from a single-center prospective interventional single-arm clinical trial
55th Annual Conference of the Society of Nuclear Medicine (SNMICON), November 16-19, 2023, Jodhpur, India,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 64, 2023, Nr. Suppl. 1, P706 -
68Ga-NeoB PET for Glioma and Breast Cancer : First Results from a Prospective Observational Trial
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. 1 supplement, S. S265 -
68Ga-SSO-120 versus 18F-FDG PET in the Initial Staging of Small-Cell Lung Cancer PatientsIn: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. Suppl. 1, Annual Congress of the European Association of Nuclear Medicine September 9–13, 2023 Vienna, Austria, S. 488 – S489
-
68Ga-Satoreotide PET for Staging of Small-Cell Lung Cancer PatientsIn: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 64, 2023, Nr. Suppl. 1, P165
-
A retrospective multicenter analysis of the incidence of bone only disease at PSMA PET/CT in Castration Resistant Prostate Cancer (CRPC) patients
55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON); NOV 16-19, 2023; Jodhpur, India,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 64, 2023, Nr. Suppl. 1, P299 -
Analysing the Tumour Transcriptome of Prostate Cancer to Predict Efficacy of Lu-PSMA Therapy
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. 1 supplement, S. S180 -
Can we rely on available models to identify candidates for extended Pelvic Lymph Node Dissection (ePLND) in men staged with PSMA-PET? : External validation of the Briganti nomograms and development of a novel tool to identify optimal candidates for ePLND
38th Annual EAU (European Association of Urology) Congress ; EAU23 ; 10 - 13 March 2023, Milan, Italy,In: European Urology. Amsterdam: Elsevier, Jg. 83, 2023, Nr. Supplement 1, S. S923 – S924 -
Do Bone Scans Over Stage Disease Compared to PSMA PET? : An international multicenter retrospective study with blinded independent readers
55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON); NOV 16-19, 2023; Jodhpur, India,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 64, 2023, Nr. Suppl. 1, P1094 -
Fibroblast activation protein alpha (FAPα) directed imaging and radioligand therapy in patients with solitary fibrous tumor (SFT)
55th Annual Conference of the Society of Nuclear Medicine (SNMICON), November 16-19, 2023, Jodhpur, India,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 64, 2023, Nr. Suppl. 1, P714 -
From CHAARTED low- and high-volume disease to PSMA PET imaging volume in mHSPC patients : an international multicenter retrospective study
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. 1 supplement, S. S230 – S231 -
Head-to-head comparison of68Ga-FAPI46 PET/CT,18F-FDG PET/CT, and contrast- enhanced CT in patient with various solid tumors
Annual Congress of the European Association of Nuclear Medicine, 9-13 September, 2023, Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. 1 supplement, S. S166 – S167 -
Identifying the optimal candidates for a super-extended staging pelvic lymph-node dissection in prostate cancer patients treated in the PET-PSMA era : Results from a multi-institutional series
38th Annual EAU (European Association of Urology) Congress ; EAU23 ; 10 - 13 March 2023, Milan, Italy,In: European Urology. Amsterdam: Elsevier, Jg. 83, 2023, Nr. Supplement 1, S. S925 – S926 -
Improving prediction of local stage by PSMA-PET : Development of a novel integrated tool for extracapsular extension and seminal vesicle invasion combining clinical and imaging features in localized prostate cancer
38th Annual European Association of Urology (EAU) Congress ; March 10 - 13, 2023, Milan, Italy,In: European Urology. Amsterdam: Elsevier, Jg. 83, 2023, Nr. Supplement 1: Abstracts EAU23, S. S1778 – S1779 -
Improving radical prostatectomy with intraoperative ex-vivo PSMA-PET/CT imaging
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. 1 supplement, S. S586 -
Inter-institutional differences and common ground in 177Lu-PSMA radionuclide therapy : International survey in 95 theranostic centers
55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON); NOV 16-19, 2023; Jodhpur, India,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 64, 2023, Nr. Suppl. 1, P843 -
Inter-institutional differences and common ground in 177Lu-PSMA radionuclide therapy : International survey in 95 theranostic centersIn: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. Suppl. 1, S. S92
-
Intraoperative microPET/CT imaging for PSMA-positive cancer foci in radical prostatectomy – feasibility study
38th Annual EAU (European Association of Urology) Congress ; EAU23 ; 10 - 13 March 2023, Milan, Italy,In: European Urology. Amsterdam: Elsevier, Jg. 83, 2023, Nr. Supplement 1, S. S687 -
Performance Evaluation of 18F-PSMA and 68Ga-PSMA in a Novel MicroPET/CT System Dedicated to Radioguided Surgery
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023, Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. 1 supplement, S. S131 -
Practical RECIP : Visual assessment of Response Evaluation Criteria In PSMA-PET/CT in metastatic castration-resistant prostate cancer
55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON); NOV 16-19, 2023; Jodhpur, India,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 64, 2023, Nr. Suppl. 1, P1619 -
Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: a surrogate of Pelvic Lymph Node Dissection? : Follow-up analysis of a Multicenter Prospective Phase 3 Imaging Trial
55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON); NOV 16-19, 2023; Jodhpur, India,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 64, 2023, Nr. Suppl. 1, P440 -
Prognostic value of the post-treatment 177Lu-DOTATOC scintigraphy in NET patients undergoing PRRT
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023, Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. 1 supplement, S. S134 -
Prostate Cancer Molecular Imaging Standardized Evaluation : The PROMISE V2 Framework Including Response Evaluation for Clinical TrialsIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics. Heidelberg: Springer, Jg. 199, 2023, Nr. Suppl. 1, S. S150DOI (Open Access)
-
Safety and Efficacy of Extended 177Lu-PSMA Therapy: Multi-Center Retrospective Analysis
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. 1 supplement, S. S152 -
Safety and effectiveness of Lutetium-177–Prostate-Specific Membrane Antigen in patients with metastatic castration-resistant prostate cancer with and without visceral metastases who had received prior radium-223 : A post hoc analysis of the RALU study
55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON); NOV 16-19, 2023; Jodhpur, India,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 64, 2023, Nr. Suppl. 1, P607 -
The Updated Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE V2.0) Framework for Standardized Reporting of PSMA-PET
Annual Congress of the European Association of Nuclear Medicine, 19-13 September 2023, Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. 1 supplement, S. S177 -
Therapiepause nach 2 Jahren Immuntherapie bei einer metabolischen Komplettremission beim NSCLC
63. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.,In: Pneumologie. Stuttgart: Thieme, Jg. 77, 2023, Nr. S 01, S. S46 -
Updated Automated PROMISE assessment : Treatment response evaluation approach on metastatic prostate cancer patients based on PSMA PET/CT
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. 1 supplement, S. S18 -
68GA-FAPI PET/CT in the evaluation of Non-Small Cell Lung Cancer (NSCLC)
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S107DOI (Open Access) -
Changes in Tumor-Blood Ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S80DOI (Open Access) -
FAPI, PSMA and FDG PET/CT in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) : a triple tracer comparison
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine October ; 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S118 – S119DOI (Open Access) -
Impact of PSMA PET/CT on prostate cancer salvage radiotherapy management : Results from the prospective randomized phase 3 trial [PSMA SRT NCT03582774]In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 40, 2022, Nr. 16_Suppl., S. 5028
-
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT : Comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S267DOI (Open Access) -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : an international multicenter study
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S269DOI (Open Access) -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : An international multicenter study
EAU22: 37th Annual EAU Congress, 01.-04.07.2022, Amsterdam,In: European Urology. Amsterdam: Elsevier, Jg. 81, 2022, Nr. Supplement 1: Abstracts EAU22 - 37th Annual EAU Congress, S. S794 – S795 -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : an international multicenter study
2022 ASCO Genitourinary Cancers Symposium, 17.-19.02.2022, San Fransisco,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 40, 2022, Nr. 6, Supplement: 2022 ASCO Genitourinary Cancers Symposium, jnumed.121.263072DOI (Open Access) -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP) : An international multicenter studyIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 40, 2022, Nr. Suppl. 6, 42DOI, Online Volltext (Open Access)
-
PSMA PET disease extent for European Association of Urology biochemical recurrence risk groups : An international multicentre study
EAU22: 37th Annual EAU Congress, 01.-04.07.2022, Amsterdam,In: European Urology. Amsterdam: Elsevier, Jg. 81, 2022, Nr. Supplement 1: Abstracts EAU22 - 37th Annual EAU Congress, S. S291 -
PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy : An international multicenter retrospective studyIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 40, 2022, Nr. 16_Suppl., S. 5043DOI (Open Access)
-
PSMA-directed imaging and therapy of salivary gland tumors : a single-center retrospective study
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S229DOI (Open Access) -
Predicting the outcome of mCPRC patients after Lu-177 PSMA therapy using semi-quantitative and visual criteria in baseline PSMA PET : An international multicenter retrospective studyIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 40, 2022, Nr. Suppl. 6, 32DOI (Open Access)
-
Radiation Exposure of I-124-MIBG Imaging in Adult Patients with Neuroendocrine Tumours
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S36 – S37DOI (Open Access) -
Re: Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection prior to Radical Prostatectomy and Pelvic Lymph Node Dissection : A Multicenter Prospective Phase 3 Imaging TrialIn: The Journal of Urology. Philadelphia; Hagerstown, Md.: Lippincott Williams & Wilkins, Jg. 207, 2022, Nr. 4, S. 930
-
Safety and Effectiveness of Lutetium-177-Prostate-Specific Membrane Antigen (177Lu-PSMA) Therapy Used in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Radium-223 (223Ra) : The RALU Study
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S54 – S55DOI (Open Access) -
Safety and efficacy of [90Y]Y-FAPI-46 radioligand therapy in patients with advanced sarcomas and other cancer entities
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 33, 2022, Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S1231 – S1232DOI (Open Access) -
Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra) : Interim analysis of the RALU studyIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 40, 2022, Nr. 16_Suppl., S. 5040 – 5040
-
Superiority of [68Ga]Ga-FAPI-46 over [18F]F-FDG PET/CT for cholangiocarcinoma imaging
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S192 – S193DOI (Open Access) -
Target Expression and FAP-Directed Tumour Imaging in a Large, Single-Centre PET Database of 324 Patients and 21 Tumour Entities
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S119 – S120DOI (Open Access) -
VISION read criteria of 68Ga-PSMA-11 PET scans for patient eligibility to 177Lu-PSMA-617 therapy : a simple and reproducible methodology
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S129 – S130DOI (Open Access) -
A novel theranostic approach for sarcoma : Insights on diagnostic and therapeutic use of FAP-radioligands
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment. Basel: Karger, Jg. 44, 2021, Nr. Supplement 2, S. 11 – 12DOI (Open Access) -
Complete metabolic response in advanced non-small cell lung cancer patients with prolonged response to immune checkpoint inhibitor therapyIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 39, 2021, Nr. 15_Suppl, S. 9050 – 9050DOI (Open Access)
-
Development of a novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP) : An international multicenter study
EANM‘21 ; 34th Annual Congress of the European Association of Nuclear Medicine ; October 20-23, 2021, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 48, 2021, Nr. Suppl. 1, S. S311 – S312DOI (Open Access) -
Dynamic Ga-68-DOTA PET/CT and Compartmental Modelling to Non-invasively Estimate the Glomerular Filtration RateIn: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 62, 2021, Nr. Suppl. 1, 88
-
Efficacy and safety of 124-I-MIBG guided high activity 131-I-MIBG therapy of metastatic pheochromocytoma and neuroblastomaIn: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 48, 2021, Nr. Suppl. 1, S. 290 – S291
-
Evaluation of Dynamic Renal Ga-68-DOTA PET/CT to Monitor the Urinary Efflux and to Estimate the Glomerular Filtration Rate Using a Compartmental Kinetic Modelling ApproachIn: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 48, 2021, Nr. Suppl. 1, S. 340
-
FDG-PET avidity as a prognostic biomarker for overall survival in renal cell carcinoma
2021 ASCO Annual Meeting, 4. - 8. June 2021, virtuell,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 39, 2021, Nr. Suppl. 15, S. e16564DOI (Open Access) -
Ga-68-FAPI for sarcoma imaging : Data from the FAPI-PET prospective observational trial
2021 SNMMI Annual Meeting, June 11th to June 15th, 2021, virtual,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 62, 2021, Nr. Suppl. 1, 126 -
Ga-68-versus F-18-PSMA for Cerenkov Luminescence and autoradiography in a prostate cancer mouse model
EANM‘21, Annual Congress of the European Association of Nuclear Medicine, October 20-23, 2021, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 48, 2021, Nr. Suppl. 1, S. S17DOI (Open Access) -
Imaging Properties and Quantification Accuracy of Ga-68 and I-124 in a New Generation Preclinical PET/CT System : A Phantom StudyIn: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 48, 2021, Nr. Suppl. 1, S. 227 – S228
-
Impact of PSMA PET/CT on SRT planning : Preliminary results from the randomized phase III trial NCT03582774
2021 Genitourinary Cancers Symposium, 11 - 13 Feb 2021, online,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 39, 2021, Nr. 6, Supplement, S. 30 – 30DOI (Open Access) -
Initial clinical experience with [Y-90]Y-FAPI-46 radioligand therapy for advanced stage solid tumors
Annual Congress of the European Association of Nuclear Medicine, October 20-23, 2021, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 48, 2021, Nr. Suppl. 1, S. S290DOI (Open Access) -
Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET) : An explorative, multicenter studyIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 39, 2021, Nr. 15_Suppl, S. 5066 – 5066DOI (Open Access)
-
Nomograms to predict outcome after LuPSMA radionuclide therapy in men with metastatic castration-resistant prostate cancer : An international multicenter retrospective studyIn: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 48, 2021, Nr. Suppl. 1, S. 63 – S64
-
PSMA PET and radiomics for the evaluation of liver metastases in castration-resistant prostate cancer patients : A multicenter retrospective studyIn: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 48, 2021, Nr. Suppl. 1, S. 234
-
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT] : Study Protocol
AACR Annual Meeting 2021, April 10-15, 2021 and May 17-21, 2021, Philadelphia, PA, USA,In: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 81, 2021, Nr. Suppl. 13, CT257 -
Phase III randomized trial of PSMA PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT] : Study protocol NCT04457245
2021 Genitourinary Cancers Symposium, 11 - 13 Feb 2021, online,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 39, 2021, Nr. 6, Supplement, S. TPS172DOI (Open Access) -
Visualization of fibroblast activation after myocardial infarction using 68Ga-FAPI-PETIn: European Heart Journal. Oxford: Oxford University Press (OUP), Jg. 42, 2021, Nr. Supplement_1, ehab724.0255DOI (Open Access)
-
Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection : A multicenter prospective phase III imaging study.
2020 ASCO Annual Meeting, May 29-31, 2020, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 38, 2020, Nr. Suppl. 15, 5502DOI (Open Access) -
Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection : A multicenter prospective phase III imaging study
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 47, 2020, Nr. Supplement 1, S. S209DOI (Open Access) -
Comparison of Lesion Detectability and Image Quality among Digital and Analog PET Systems for Recurrence in Thyroid Cancer Patients Using I-124
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 47, 2020, Nr. Supplement 1, S. S429DOI (Open Access) -
Digital high sensitivity I-124 PET/CT improves the detectability of thyroid cancer metastases
Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, July, 11-14, 2020, Virtual,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 61, 2020, Nr. Suppl. 1, 255Online Volltext (Open Access) -
Effects of anti-TNF-therapy on osteoblastic activity in ankylosing spondylitis : Results from a prospective study using PET-MRI of SIJ and SPINE
EULAR: Annual European Congress of Rheumatology, 2020, 03.-06.06.2020, Frankfurt,In: Annals of the Rheumatic Diseases (ARD). London: BMJ Publishing Group, Jg. 79, 2020, Nr. Suppl. 1, S. 1125 – 1126DOI (Open Access) -
Efficacy and safety of 177Lu-PSMA radionuclide treatment in patients with diffuse bone marrow involvement : a multicenter retrospective study
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 47, 2020, Nr. Supplement 1, S. S491DOI (Open Access) -
Efficacy and safety of Lu ¹⁷⁷-PSMA radionuclide treatment in patients with diffuse bone marrow involvement : A multicenter retrospective study
2020 ASCO Annual Meeting, May 29-31, 2020, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 38, 2020, Nr. Suppl. 15, e17543DOI (Open Access) -
Efficacy and safety of Lu-177-PSMA radionuclide treatment in patients with diffuse bone marrow involvement : a multicenter retrospective study
Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), July 11-14, 2020, Virtual,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 61, 2020, Nr. Suppl. 1, 1284Online Volltext (Open Access) -
Evaluation of 68Ga-PSMA PET/CT Images Acquired with a Reduced Scan Time Duration in Prostate Cancer Patients using a Digital PET/CT Scanner
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 47, 2020, Nr. Supplement 1, S. S27DOI (Open Access) -
Impact of PSMA PET/CT on SRT planning: Preliminary results from a randomized phaseIII trial
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 47, 2020, Nr. Supplement 1, S. 22DOI (Open Access) -
Lymphonodular anthracosis in patients undergoing FDG PET/CT for initial lung cancer diagnostics and/or staging is a mayor pitfall : a comparison to the histological gold standard
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 47, 2020, Nr. Supplement 1, S. S565 – S566DOI (Open Access) -
Mapping prostate cancer lesions pre/post unsuccessful salvage lymph node dissection employing PSMA-PET
Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, July, 11-14, 2020, Virtual,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 61, 2020, Nr. Suppl. 1, 1270Online Volltext (Open Access) -
Overall survival after177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrateresistant prostate cancer : Post-hoc analysis of a prospective phase II trial
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 47, 2020, Nr. Supplement 1, S. S488DOI (Open Access) -
PERCIST-derived metabolic volume response predicts overall and progression-free survival in patients with malignant pleural mesothelioma treated with Pembrolizumab
Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, July 11-14, 2020, Virtual,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 61, 2020, Nr. Suppl. 1, 243Online Volltext (Open Access) -
PERCIST-derived metabolic volume response predicts overall and progression-free survival in patients with malignant pleural mesothelioma treated with Pembrolizumab
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 47, 2020, Nr. Supplement 1, S. S353DOI (Open Access) -
PSMA-PET identifies PCWG3 target populations with high concordance however superior reproducibility when compared to conventional imaging
Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), July 11-14, 2020, Virtual,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 61, 2020, Nr. Suppl. 1, 1260 -
Predictive factors and prediction nomograms for LuPSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer : an international multicentre retrospective study
Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), July 11-14, 2020, Virtual,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 61, 2020, Nr. Suppl. 1, 593Online Volltext (Open Access) -
Preliminary Investigations on Radiation Exposure in [68Ga]Ga-PSMA-11 based Cerenkov Luminescence Imaging Procedures
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 47, 2020, Nr. Supplement 1, S. S212DOI (Open Access) -
Prognostic markers for overall survival and outcome to LuPSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer
2020 ASCO Annual Meeting, May 29-31, 2020, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 38, 2020, Nr. 15, Suppl., 5548DOI (Open Access) -
Prognostic markers for overall survival and outcome to LuPSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 47, 2020, Nr. Supplement 1, S. S487DOI (Open Access) -
Prostate PET Applications Beyond Staging and Restaging
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 47, 2020, Nr. Supplement 1, S. S22DOI (Open Access) -
Salvage therapies for PSMA PET-positive nodal recurrent prostate cancerIn: Radiotherapy and Oncology (The Green Journal). Amsterdam: Elsevier, Jg. 152, 2020, Nr. Supplement 1, S. 614
-
Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma
ESMO Virtual Congress 2020, 19.-21.09- und 16.-18.10.2020,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 31, 2020, Nr. Suppl. 4, S. S1076 – S1077DOI (Open Access) -
Prospective head-to-head comparative phase 3 study between 18F-fluciclovine and 68Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer
2019 ASCO Annual Meeting, May 31 - June 4, 2019, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 37, 2019, Nr. 15, 5014DOI (Open Access) -
RESIST-PC phase 2 trial : 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer
2019 ASCO Annual Meeting, May 31 - June 4, 2019, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 37, 2019, Nr. 15, 5028DOI (Open Access) -
Randomized prospective phase 3 trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
2019 ASCO Annual Meeting, May 31 - June 4, 2019, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 37, 2019, Nr. 15, Suppl., TPS5101DOI (Open Access) -
Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer : Preliminary results from a phase 2/3 prospective trial
2018 ASCO Annual Meeting, June 1-5, 2018, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 36, 2018, Nr. 15, Suppl., 5001DOI (Open Access) -
Comparison of 68Ga-PSMA-11 PET/CT and F-18-Fluciclovine PET/CT in recurrent Prostate Cancer
Annual Congress of the European Association of Nuclear Medicine, October 13 – 17, 2018 Düsseldorf, Germany,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 45, 2018, Nr. Suppl. 1, S. S150 -
68Ga-FAPI-46 PET/CT for cancer imaging : Results of a single-center, prospective, interventional, single-arm clinical trial
2025 ASCO Genitourinary Cancers Symposium, February 13-15, 2025, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 43, 2025, Nr. 5, Supplement, 457 -
A phase I/II study of neoadjuvant, intra-arterial administration of (177Lu)lutetium vipivotide tetraxetan in subjects with high-risk, localised or locally advanced prostate cancer (LUPUS)
2025 ASCO Genitourinary Cancers Symposium, February 13-15, 2025, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 43, 2025, Nr. 5, Supplement, TPS431 -
Association of PSMA PET results at biochemical recurrence (BCR) with metastasis free survival (MFS) by conventional imaging (CI) in patients with locally advanced or high-risk localized prostate cancer initially treated with radical prostatectomy (RP) : A retrospective multicenter study
2025 ASCO Genitourinary Cancers Symposium, 13 - 15 February 2025, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 43, 2025, Nr. 5, Supplement, 355 -
Implementation and preliminary validity of the Functional Assessment of Cancer Therapy : Radionuclide Therapy (FACT-RNT) in patients receiving radionuclide therapy for prostate cancer
2025 ASCO Genitourinary Cancers Symposium, January 13-15, 2025, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 43, 2025, Nr. 5, Supplement, 118 -
Machine learning integration for prognostic modeling in PSMA-PET-driven salvage radiotherapy for biochemical recurrence post-prostatectomy
ESTRO 2025, 2-6 May 2025, Vienna, Austria,In: Radiotherapy and Oncology (The Green Journal). Amsterdam: Elsevier, Jg. 206, 2025, Nr. Supplement 1, S. S3851 – S3852 -
Prostate cancer risk groups by PSMA-PET PROMISE (PPP) : Results from an international multi-center registry study
2025 ASCO Genitourinary Cancers Symposium, January 13-15, 2025, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 43, 2025, Nr. 5, Supplement, 266 -
A randomized phase I/II study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with or without ipilimumab in patients with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI trial)
2024 ASCO Genitourinary Cancers Symposium, January 25-27, 2024, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 42, 2024, Nr. 4, Supplement, TPS352 -
Low- and high-volume disease in mHSPC, from CHAARTED to PSMA-PET : An international multicenter retrospective study
2024 ASCO Genitourinary Cancers Symposium, January 25-27, 2024, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 42, 2024, Nr. 4, Supplement, 44 -
Response evaluation criteria in PSMA PET/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer
2024 ASCO Genitourinary Cancers Symposium, January 25–27, 2024, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 42, 2024, Nr. 4, Supplement, 45 -
Update from the PSMA-dRT trial : A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer
2024 ASCO Genitourinary Cancers Symposium, January 25–27, 2024, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 42, 2024, Nr. Supplement 4, S. 291 – 291 -
68Ga-FAPI PET/CT novel diagnostic tool in sarcoma
Annual Congress of the European Association of Nuclear Medicine, 9-13 September, 2023, Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. 1 supplement, S. S414 – S415 -
Low- and high-volume disease in mHSPC : From CHAARTED to PSMA PET
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 34, 2023, Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S967 -
Comparison of the Safety and Tolerability of Paraaminohippurate (PAH) and Amino Acid (AA) Co-Infusion in Patients with Neuroendocrine Tumours Receiving Peptide Receptor Radionuclide Therapy (PRRT) : A Case Series of Eight Patients
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine October ; 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S579DOI (Open Access) -
Immuntherapie eines Mikrosatelliten-instabilen metastasierten Talgdrüsenkarzinoms der Glandula submandibularis mit Pembrolizumab
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment. Basel: Karger, Jg. 45, 2022, Nr. Supplement 2, S. 230 – 231DOI (Open Access) -
Lesion Quantification Accuracy of Digital 90Y PET Imaging in the Context of Dosimetry in Systemic FAPI Radionuclide Therapy
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S636DOI (Open Access) -
Metastasenfreies Überleben und Fernmetastasen-Muster nach PSMA-PET-gesteuerter Salvage-Radiotherapie bei rezidivierendem oder persistierendem Prostatakarzinom nach Prostatektomie
28. Kongress der Deutschen Gesellschaft für Radioonkologie ; DEGRO 2022 ; 26. bis 28.05.2022, Stuttgart, Germany,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics. Heidelberg: Springer, Jg. 198, 2022, Nr. Supplement 1, S. S117DOI (Open Access) -
Additional Benefit of FDG-PET when Discontinuing Immune Checkpoint Inhibitor Therapy in Patients with metastatic Melanoma
31. Deutscher Hautkrebskongress (ADO-Jahrestagung), 8.–11. September 2021, Hamburg, Germany and Virtual,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 19, 2021, Nr. Suppl. 4, S. 75 – 76DOI (Open Access) -
Emission time optimisation for [68Ga]Ga-PSMA-11 with a SiPM PET/CT based on phantom measurements
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 47, 2020, Nr. Supplement 1, S. S256DOI (Open Access) -
Emission time reduction for 2-[18F]FDG examinations in lymphoma patients with a PET/CT with SiPM - a feasibility phantom study
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 47, 2020, Nr. Supplement 1, S. S257 – S258DOI (Open Access)